MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$173,858K
Proceeds from issuances
of common stock...
$8,100K
Net cash provided by
(used in) investing...
$72,463K
Net cash provided by
financing activities
$8,100K
Canceled cashflow
$101,395K
Net cash increase
(decrease) for the period
-$14,579K
Canceled cashflow
$80,563K
Stock-based compensation
$28,006K
Accounts payable,
accrued expenses and...
$3,369K
Depreciation
$546K
Right-of-use assets and lease
liabilities, net
$83K
Purchases of marketable
securities
$101,254K
Purchases of property and
equipment
$141K
Net cash used in
operating activities
-$95,142K
Canceled cashflow
$32,004K
Net loss
-$119,947K
Prepaid expenses and
other assets
$5,080K
Accretion on marketable
securities, net
-$2,119K
Back
Back
Cash Flow
source: myfinsight.com
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)